388 related articles for article (PubMed ID: 18544735)
1. Better prioritization may speed approval of adjuvant therapies in breast cancer.
Tuma RS
J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
[No Abstract] [Full Text] [Related]
2. When are "positive" clinical trials in oncology truly positive?
Ocana A; Tannock IF
J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
[TBL] [Abstract][Full Text] [Related]
3. Dual-action drug approved for use in advanced breast cancer.
McBride D
ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
[No Abstract] [Full Text] [Related]
4. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
5. Advances in the treatment of breast cancer.
Moulder S; Hortobagyi GN
Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the hormonal treatment of breast cancer.
Boughey JC; Buzdar AU; Hunt KK
Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
[No Abstract] [Full Text] [Related]
7. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
Bardia A; Baselga J
Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
[TBL] [Abstract][Full Text] [Related]
8. The American Society of Clinical Oncology 2009 Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009.
Quill T; Abair T; Garcia K
Clin Breast Cancer; 2009 Nov; 9(4):213-8. PubMed ID: 19933075
[No Abstract] [Full Text] [Related]
9. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
[TBL] [Abstract][Full Text] [Related]
10. FDA approves new drug for specific type of advanced breast cancer.
Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
[No Abstract] [Full Text] [Related]
11. Femara approved as first-line breast cancer therapy.
FDA Consum; 2001; 35(3):5. PubMed ID: 11458552
[No Abstract] [Full Text] [Related]
12. Accelerated approval of oncology drugs: can we do better?
Ellenberg SS
J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
[No Abstract] [Full Text] [Related]
13. Bioregulatory niches in breast cancer.
Sledge GW
Clin Breast Cancer; 2006 Aug; 7(3):200. PubMed ID: 16942636
[No Abstract] [Full Text] [Related]
14. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
Schilsky RL
J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
[No Abstract] [Full Text] [Related]
15. Swimming upstream: an advocate reflects on cancer research and social realities.
Mayer M
J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
[No Abstract] [Full Text] [Related]
16. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
17. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
Edwards S
Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
[No Abstract] [Full Text] [Related]
18. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
19. [Early-stage breast cancer - strategies for adjuvant systemic therapy].
Görner M; Just M; Gerull S
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):230-8. PubMed ID: 18716990
[TBL] [Abstract][Full Text] [Related]
20. Cancer and leukemia group B breast committee: decades of progress and plans for the future.
Hudis CA; Winer EP
Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3576s-80s. PubMed ID: 16740788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
